POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (5.6.2021, 11:21am CEST, WHO):   U.S. 44,834    India 412,262    Brazil 77,359    France 23,116    Turkey 28,997    Russia 7,975    The United Kingdom 1,946    Italy 9,113    Spain 2,431    Germany 18,034    Argentina 26,238    Columbia 14,551    Poland 3,899    Iran 15,872    Mexico 3,064    Ukraine 2,546    Peru 4,562    Indonesia 5,285    Czechia 2,412    South Africa 1,187    The Netherlands 7,830    Canada 6,708    Chile 3,885    Iraq 5,813    Philippines 5,685    Sweden 3,058    Pakistan 4,113    Hungary 1,130    Bangladesh 1,742    Jordan 1,220    Serbia 1,304    Austria 1,297    Japan 3,763    Lebanon 1,012    United Arab Emirates 1,954    Malaysia 3,744    Saudi Arabia 1,016    Ecuador 1,806    Nepal 8,605    Greece 1,368    Croatia 2,494    Azerbaijan 1,381    Georgia 2,171    Tunisia 1,448    Bolivia 1,588    Paraguay 2,214    Kuwait 1,451    Costa Rica 1,304    Lithuania 1,249    Egypt 1,102    Guatemala 1,194    Honduras 1,358    Uruguay 2,826    Bahrain 1,450    Sri Lanka 1,939    Cuba 1,010    Thailand 1,911    Mongolia 1,128    Réunion 1,070    China 18    Singapore 16    New Zealand 4    Australia 13    South Korea 574   

U.S. authorizes Moderna's coronavirus vaccine for emergency use

Christian Fernsby |
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus.

Article continues below



Topics: U.S.   

The emergency use authorization allows the Moderna coronavirus Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.

The totality of the available data provides clear evidence that the Moderna coronavirus Vaccine may be effective in preventing coronavirus.

The data also show that the known and potential benefits outweigh the known and potential risks—supporting the company’s request for the vaccine’s use in people 18 years of age and older.

In making this determination, the FDA can assure the public and medical community that it has conducted a thorough evaluation of the available safety, effectiveness, and manufacturing quality information.

The Moderna coronavirus Vaccine contains messenger RNA (mRNA), which is genetic material. The vaccine contains a small piece of the coronavirus virus’s mRNA that instructs cells in the body to make the virus’s distinctive “spike” protein.

After a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against coronavirus.

Moderna coronavirus Vaccine is administered as a series of two doses, one month apart. The available safety data to support the EUA include an analysis of 30,351 participants enrolled in an ongoing randomized, placebo-controlled study conducted in the U.S.

These participants, 15,185 of whom received the vaccine and 15,166 of whom received saline placebo, were followed for a median of more than two months after receiving the second dose.

The most commonly reported side effects, which typically lasted several days, were pain at the injection site, tiredness, headache, muscle pain, chills, joint pain, swollen lymph nodes in the same arm as the injection, nausea and vomiting, and fever.

Of note, more people experienced these side effects after the second dose than after the first dose, so it is important for vaccination providers and recipients to expect that there may be some side effects after either dose, but even more so after the second dose.

The effectiveness data to support the EUA include an analysis of 28,207 participants in the ongoing randomized, placebo-controlled U.S. study who did not have evidence of coronavirus infection prior to the first dose of vaccine. Among these participants, 14,134 received the vaccine and 14,073 received placebo.

After the analysis of these 196 cases was completed, one severe case in the vaccine group was identified and is awaiting confirmation.

At this time, data are not available to determine how long the vaccine will provide protection, nor is there evidence that the vaccine prevents transmission of coronavirus from person to person.


What to read next

U.S. begins final tests of coronavirus vaccine candidate
FDA issues emergency use authorization for first U.S. coronavirus vaccine
DNA-based vaccine guards against Zika in monkey study